Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Breast Cancer | Research

SLC6A8-mediated intracellular creatine accumulation enhances hypoxic breast cancer cell survival via ameliorating oxidative stress

Authors: Qiao Li, Manran Liu, Yan Sun, Ting Jin, Pengpeng Zhu, Xueying Wan, Yixuan Hou, Gang Tu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Background

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with poor prognosis and limited treatment options. Hypoxia is a key hallmark of TNBC. Metabolic adaptation promotes progression of TNBC cells that are located within the hypoxic tumor regions. However, it is not well understood regarding the precise molecular mechanisms underlying the regulation of metabolic adaptions by hypoxia.

Methods

RNA sequencing was performed to analyze the gene expression profiles in MDA-MB-231 cell line (20% O₂ and 1% O₂). Expressions of Slc6a8, which encodes the creatine transporter protein, were detected in breast cancer cells and tissues by quantitative real-time PCR. Immunohistochemistry was performed to detect SLC6A8 protein abundances in tumor tissues. Clinicopathologic correlation and overall survival were evaluated by chi-square test and Kaplan-Meier analysis, respectively. Cell viability assay and flow cytometry analysis with Annexin V/PI double staining were performed to investigate the impact of SLC6A8-mediated uptake of creatine on viability of hypoxic TNBC cells. TNBC orthotopic mouse model was used to evaluate the effects of creatine in vivo.

Results

SLC6A8 was aberrantly upregulated in TNBC cells in hypoxia. SLC6A8 was drastically overexpressed in TNBC tissues and its level was tightly associated with advanced TNM stage, higher histological grade and worse overall survival of TNBC patients. We found that SLC6A8 was transcriptionally upregulated by p65/NF-κB and mediated accumulation of intracellular creatine in hypoxia. SLC6A8-mediated accumulation of creatine promoted survival and suppressed apoptosis via maintaining redox homeostasis in hypoxic TNBC cells. Furthermore, creatine was required to facilitate tumor growth in xenograft mouse models. Mechanistically, intracellular creatine bolstered cell antioxidant defense by reducing mitochondrial activity and oxygen consumption rates to reduce accumulation of intracellular reactive oxygen species, ultimately activating AKT-ERK signaling, the activation of which protected the viability of hypoxic TNBC cells via mediating the upregulation of Ki-67 and Bcl-2, and the downregulation of Bax and cleaved Caspase-3.

Conclusions

Our study indicates that SLC6A8-mediated creatine accumulation plays an important role in promoting TNBC progression, and may provide a potential therapeutic strategy option for treatment of SLC6A8 high expressed TNBC.

Available only for authorised users

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.CrossRefPubMed

Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, et al. Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers (Basel). 2020;12(9):2392.CrossRef

Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157. https://doi.org/10.1186/s12943-019-1089-9.CrossRefPubMedPubMedCentral

Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol. 2014;24(8):472–8. https://doi.org/10.1016/j.tcb.2014.06.001.CrossRefPubMedPubMedCentral

Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52(2):192–203. https://doi.org/10.1038/s12276-020-0384-2.CrossRefPubMedPubMedCentral

Yang Y, Karakhanova S, Hartwig W, D'Haese JG, Philippov PP, Werner J, et al. Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy. J Cell Physiol. 2016;231(12):2570–81. https://doi.org/10.1002/jcp.25349.CrossRefPubMed

Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417(1):1–13. https://doi.org/10.1042/BJ20081386.CrossRefPubMed

Kim J, Kim J, Bae JS. ROS homeostasis and metabolism: a critical liaison for cancer therapy. Exp Mol Med. 2016;48(11):e269. https://doi.org/10.1038/emm.2016.119.CrossRefPubMedPubMedCentral

Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer. 2014;14(11):709–21. https://doi.org/10.1038/nrc3803.CrossRefPubMedPubMedCentral

10.

Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009;10(4):273–84. https://doi.org/10.1016/j.cmet.2009.08.015.CrossRefPubMedPubMedCentral

11.

Parks SK, Cormerais Y, Marchiq I, Pouyssegur J. Hypoxia optimises tumour growth by controlling nutrient import and acidic metabolite export. Mol Asp Med. 2016;47-48:3–14.CrossRef

12.

Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond). 2018;38(1):12. https://doi.org/10.1186/s40880-018-0288-x.CrossRef

13.

Skelton MR, Schaefer TL, Graham DL, Degrauw TJ, Clark JF, Williams MT, et al. Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency. PLoS One. 2011;6(1):e16187. https://doi.org/10.1371/journal.pone.0016187.CrossRefPubMedPubMedCentral

14.

Stockebrand M, Sasani A, Das D, Hornig S, Hermans-Borgmeyer I, Lake HA, et al. A mouse model of Creatine transporter deficiency reveals impaired motor function and muscle energy metabolism. Front Physiol. 2018;9:773. https://doi.org/10.3389/fphys.2018.00773.CrossRefPubMedPubMedCentral

15.

Joncquel-Chevalier Curt M, Voicu PM, Fontaine M, Dessein AF, Porchet N, Mention-Mulliez K, et al. Creatine biosynthesis and transport in health and disease. Biochimie. 2015;119:146–65. https://doi.org/10.1016/j.biochi.2015.10.022.CrossRefPubMed

16.

Peleli M, Ferreira DMS, Tarnawski L, McCann Haworth S, Xuechen L, Zhuge Z, et al. Dietary nitrate attenuates high-fat diet-induced obesity via mechanisms involving higher adipocyte respiration and alterations in inflammatory status. Redox Biol. 2020;28:101387. https://doi.org/10.1016/j.redox.2019.101387.CrossRefPubMed

17.

Yuan L, Wu XJ, Li WC, Zhuo C, Xu Z, Tan C, et al. SLC6A8 knockdown suppresses the invasion and migration of human hepatocellular carcinoma Huh-7 and Hep3B cells. Technol Cancer Res Treat. 2020;19:1533033820983029.CrossRef

18.

Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80(3):1107–213. https://doi.org/10.1152/physrev.2000.80.3.1107.CrossRefPubMed

19.

Loo JM, Scherl A, Nguyen A, Man FY, Weinberg E, Zeng Z, et al. Extracellular metabolic energetics can promote cancer progression. Cell. 2015;160(3):393–406. https://doi.org/10.1016/j.cell.2014.12.018.CrossRefPubMedPubMedCentral

20.

Li XH, Chen XJ, Ou WB, Zhang Q, Lv ZR, Zhan Y, et al. Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis. Int J Biochem Cell Biol. 2013;45(5):979–86. https://doi.org/10.1016/j.biocel.2013.02.003.CrossRefPubMed

21.

Ji L, Zhao X, Zhang B, Kang L, Song W, Zhao B, et al. Slc6a8-mediated creatine uptake and accumulation reprogram macrophage polarization via regulating cytokine responses. Immunity. 2019;51(2):272–284.e7.CrossRef

22.

Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer. 2016;2(12):758–70. https://doi.org/10.1016/j.trecan.2016.10.016.CrossRefPubMed

23.

Albadari N, Deng S, Li W. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discovery. 2019;14(7):667–82. https://doi.org/10.1080/17460441.2019.1613370.CrossRef

24.

Kunz M, Ibrahim SM. Molecular responses to hypoxia in tumor cells. Mol Cancer. 2003;2(1):23. https://doi.org/10.1186/1476-4598-2-23.CrossRefPubMedPubMedCentral

25.

Chamberlain KA, Chapey KS, Nanescu SE, Huang JK. Creatine enhances mitochondrial-mediated oligodendrocyte survival after demyelinating injury. J Neurosci. 2017;37(6):1479–92. https://doi.org/10.1523/JNEUROSCI.1941-16.2016.CrossRefPubMedPubMedCentral

26.

Fuhrmann DC, Brune B. Mitochondrial composition and function under the control of hypoxia. Redox Biol. 2017;12:208–15. https://doi.org/10.1016/j.redox.2017.02.012.CrossRefPubMedPubMedCentral

27.

Fuhrmann DC, Wittig I, Drose S, Schmid T, Dehne N, Brune B. Degradation of the mitochondrial complex I assembly factor TMEM126B under chronic hypoxia. Cell Mol Life Sci. 2018;75(16):3051–67. https://doi.org/10.1007/s00018-018-2779-y.CrossRefPubMed

28.

Sestili P, Martinelli C, Colombo E, Barbieri E, Potenza L, Sartini S, et al. Creatine as an antioxidant. Amino Acids. 2011;40(5):1385–96. https://doi.org/10.1007/s00726-011-0875-5.CrossRefPubMed

29.

Zhang Y, Xu Y, Lu W, Ghergurovich JM, Guo L, Blair IA, et al. Upregulation of antioxidant capacity and nucleotide precursor availability suffices for oncogenic transformation. Cell Metab. 2020;33(1):94–109.e8.CrossRef

30.

Pastor A, Collado PS, Almar M, González-Gallego J. Antioxidant enzyme status in biliary obstructed rats: effects of N-acetylcysteinefangkuo. J Hepatol. 1997;27(2):363–70. https://doi.org/10.1016/S0168-8278(97)80183-3.CrossRefPubMed

31.

Erkkilä K, Hirvonen V, Wuokko E, Parvinen M, Dunkel L. N-acetyl-L-cysteine inhibits apoptosis in human male germ cells in vitro. J Clin Endocrinol Metab. 1998;83(7):2523–31. https://doi.org/10.1210/jcem.83.7.4949.CrossRefPubMed

32.

Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, et al. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol. 2006;175(6):913–23. https://doi.org/10.1083/jcb.200512100.CrossRefPubMedPubMedCentral

33.

Liu C, Gong K, Mao X, Li W. Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma. Int J Cancer. 2011;129(6):1519–31. https://doi.org/10.1002/ijc.25817.CrossRefPubMed

34.

Paredes F, Williams HC, San Martin A. Metabolic adaptation in hypoxia and cancer. Cancer Lett. 2021;502:133–42. https://doi.org/10.1016/j.canlet.2020.12.020.CrossRefPubMed

35.

Tafani M, Sansone L, Limana F, Arcangeli T, De Santis E, Polese M, et al. The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression. Oxidative Med Cell Longev. 2016;2016:3907147.CrossRef

36.

Yu LM, Zhang WH, Han XX, Li YY, Lu Y, Pan J, et al. Hypoxia-induced ROS contribute to myoblast pyroptosis during obstructive sleep apnea via the NF-kappaB/HIF-1alpha signaling pathway. Oxidative Med Cell Longev. 2019;2019:4596368.

37.

Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;38(2):167–97. https://doi.org/10.1016/j.ccell.2020.06.001.CrossRefPubMed

38.

Lai RK, Xu IM, Chiu DK, Tse AP, Wei LL, Law CT, et al. NDUFA4L2 fine-tunes oxidative stress in hepatocellular carcinoma. Clin Cancer Res. 2016;22(12):3105–17. https://doi.org/10.1158/1078-0432.CCR-15-1987.CrossRefPubMed

39.

Rao X, Duan X, Mao W, Li X, Li Z, Li Q, et al. O-GlcNAcylation of G6PD promotes the pentose phosphate pathway and tumor growth. Nat Commun. 2015;6(1):8468. https://doi.org/10.1038/ncomms9468.CrossRefPubMedPubMedCentral

40.

Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014;39(8):347–54. https://doi.org/10.1016/j.tibs.2014.06.005.CrossRefPubMedPubMedCentral

41.

Valli A, Morotti M, Zois CE, Albers PK, Soga T, Feldinger K, et al. Adaptation to HIF1alpha deletion in hypoxic cancer cells by upregulation of GLUT14 and creatine metabolism. Mol Cancer Res. 2019;17(7):1531–44. https://doi.org/10.1158/1541-7786.MCR-18-0315.CrossRefPubMed

42.

Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, Battistelli M, et al. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med. 2006;40(5):837–49. https://doi.org/10.1016/j.freeradbiomed.2005.10.035.CrossRefPubMed

43.

Guidi C, Potenza L, Sestili P, Martinelli C, Guescini M, Stocchi L, et al. Differential effect of creatine on oxidatively-injured mitochondrial and nuclear DNA. Biochim Biophys Acta. 2008;1780(1):16–26. https://doi.org/10.1016/j.bbagen.2007.09.018.CrossRefPubMed

44.

Fimognari C, Sestili P, Lenzi M, Cantelli-Forti G, Hrelia P. Protective effect of creatine against RNA damage. Mutat Res. 2009;670(1–2):59–67. https://doi.org/10.1016/j.mrfmmm.2009.07.005.CrossRefPubMed

45.

Young JF, Larsen LB, Malmendal A, Nielsen NC, Straadt IK, Oksbjerg N, et al. Creatine-induced activation of antioxidative defence in myotube cultures revealed by explorative NMR-based metabonomics and proteomics. J Int Soc Sports Nutr. 2010;7(1):9. https://doi.org/10.1186/1550-2783-7-9.CrossRefPubMedPubMedCentral

46.

Heather LC, Cole MA, Tan JJ, Ambrose LJ, Pope S, Abd-Jamil AH, et al. Metabolic adaptation to chronic hypoxia in cardiac mitochondria. Basic Res Cardiol. 2012;107(3):268. https://doi.org/10.1007/s00395-012-0268-2.CrossRefPubMed

47.

Waypa GB, Smith KA, Schumacker PT. O2 sensing, mitochondria and ROS signaling: The fog is lifting. Mol Asp Med. 2016;47-48:76–89.CrossRef

48.

Nouws J, Nijtmans LG, Smeitink JA, Vogel RO. Assembly factors as a new class of disease genes for mitochondrial complex I deficiency: cause, pathology and treatment options. Brain. 2012;135(Pt 1):12–22. https://doi.org/10.1093/brain/awr261.CrossRefPubMed

49.

Tello D, Balsa E, Acosta-Iborra B, Fuertes-Yebra E, Elorza A, Ordonez A, et al. Induction of the mitochondrial NDUFA4L2 protein by HIF-1alpha decreases oxygen consumption by inhibiting complex I activity. Cell Metab. 2011;14(6):768–79. https://doi.org/10.1016/j.cmet.2011.10.008.CrossRefPubMed

50.

Weinberg F, Chandel NS. Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci. 2009;66(23):3663–73. https://doi.org/10.1007/s00018-009-0099-y.CrossRefPubMed

51.

Prasad S, Gupta SC, Tyagi AK. Reactive oxygen species (ROS) and cancer: role of antioxidative nutraceuticals. Cancer Lett. 2017;387:95–105. https://doi.org/10.1016/j.canlet.2016.03.042.CrossRefPubMed

52.

Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal. 2012;16(11):1295–322. https://doi.org/10.1089/ars.2011.4414.CrossRefPubMedPubMedCentral

53.

Gallorini M, Petzel C, Bolay C, Hiller KA, Cataldi A, Buchalla W, et al. Activation of the Nrf2-regulated antioxidant cell response inhibits HEMA-induced oxidative stress and supports cell viability. Biomaterials. 2015;56:114–28. https://doi.org/10.1016/j.biomaterials.2015.03.047.CrossRefPubMed

54.

Xu IM, Lai RK, Lin SH, Tse AP, Chiu DK, Koh HY, et al. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci U S A. 2016;113(6):E725–34. https://doi.org/10.1073/pnas.1508779113.CrossRefPubMedPubMedCentral

55.

Yao S, Ye J, Yin M, Yu R. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo. Cancer Lett. 2020;483:87–97. https://doi.org/10.1016/j.canlet.2020.04.003.CrossRefPubMed

Title: SLC6A8-mediated intracellular creatine accumulation enhances hypoxic breast cancer cell survival via ameliorating oxidative stress
Authors: Qiao Li
Manran Liu
Yan Sun
Ting Jin
Pengpeng Zhu
Xueying Wan
Yixuan Hou
Gang Tu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-01933-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Correction to: Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)-methyladenosine modification of MT-RNR1

Correction to: Genistein inhibits stemness of SKOV3 cells induced by macrophages co-cultured with ovarian cancer stem-like cells through IL-8/STAT3 axis

Loss of epidermal MCPIP1 is associated with aggressive squamous cell carcinoma

Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids

Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo

TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer